Compare Nutanix Inc (NTNX) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs Nuwellis Inc — how do they compare? Nutanix Inc trades at $74.05 (market cap $19.78B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Nutanix Inc is far larger — about 8990.9× Nuwellis Inc's market cap, and Nutanix Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nutanix Inc for 17 Days and Nuwellis Inc for 26 Days on average.
| NTNX | NUWE | |
|---|---|---|
Market Cap | $19.78B | $2.20M |
Volume | 1,717,619 | 121,544 |
Sector | Technology | Health |
52-Week High | $73.42 | $146.65 |
52-Week Low | $34.41 | $0.68 |
Typical Hold Time | 17 Days | 26 Days |
Enterprise Value | $18.94B | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $73.98, up 0.76% today, with a bullish technical signal from moving averages and strong recent earnings beats. The company reported robust profitability with a net income margin of 52.81% for 2026 and is recognized as a leader in multiple Gartner Magic Quadrant reports, highlighting its competitive strength in hybrid cloud infrastructure.
The outlook is positive with analyst consensus favoring a buy rating and a $76.11 price target, though risks include high valuation multiples like a 46.22 EV/EBITDA and negative ROE. Revenue growth and external storage expansion present opportunities, but investors should monitor execution against guidance and market volatility.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
